Disposition of 6387 shares by Daniel Faga of AnaptysBio at 15.3 subject to Rule 16b-3
| ANAB Stock | USD 22.47 0.91 3.89% |
About 62% of AnaptysBio's investor base is looking to short. The analysis of the overall investor sentiment regarding AnaptysBio suggests that many traders are alarmed. The current market sentiment, together with AnaptysBio's historical and current headlines, can help investors time the market. In addition, many technical investors use AnaptysBio stock news signals to limit their universe of possible portfolio assets.
AnaptysBio | Build AI portfolio with AnaptysBio Stock |
Filed transaction by AnaptysBio Director, Officer President, Ceo. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3
Read at macroaxis.com
AnaptysBio Fundamental Analysis
We analyze AnaptysBio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AnaptysBio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AnaptysBio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Debt To Equity
Debt To Equity Comparative Analysis
AnaptysBio is currently under evaluation in debt to equity category among its peers. Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
AnaptysBio Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with AnaptysBio stock to make a market-neutral strategy. Peer analysis of AnaptysBio could also be used in its relative valuation, which is a method of valuing AnaptysBio by comparing valuation metrics with similar companies.
Peers
AnaptysBio Related Equities
Complementary Tools for AnaptysBio Stock analysis
When running AnaptysBio's price analysis, check to measure AnaptysBio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AnaptysBio is operating at the current time. Most of AnaptysBio's value examination focuses on studying past and present price action to predict the probability of AnaptysBio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AnaptysBio's price. Additionally, you may evaluate how the addition of AnaptysBio to your portfolios can decrease your overall portfolio volatility.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |